UNSPSC 51271623: Bupivacaine hydrochloride monohydrate

This classification denotes an anesthetic agent with the molecular formula C18H28N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7TQO7W3VT8, chemically known as 2-piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate, but more generally known as bupivacaine hydrochloride monohydrate, which bears US NIH Compound Identifier 64737.

European Medicines Agency schedules bupivacaine hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05983MIG. Most nations, for tariff purposes, schedule bupivacaine hydrochloride monohydrate under HS 29333999. SMILES: CCCCN1CCCCC1C(=O)NC2C(CCCC2C)C.O.CL.

UNSPSC 51271623 Bupivacaine hydrochloride monohydrate is a Commodity code covering local anesthetic pharmaceutical products that state and local government healthcare facilities procure through cooperative purchasing agreements and multi-source generic drug contracts. State and local buying under this code centers on establishing framework agreements with pharmaceutical manufacturers and wholesalers to supply anesthetic injectables and related generic pharmaceuticals to public health systems, hospitals, and clinical facilities at negotiated pricing. Issuing bodies include state departments of administration and health, participating municipalities and counties within cooperative purchasing alliances, and public healthcare facilities that leverage multi-state cooperative vehicles to standardize procurement and reduce per-unit costs across jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the most recent relevant solicitation—Request for Proposal S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026, with proposals due March 26, 2026. The RFP establishes multiple contracts effective July 1, 2026, for a two-year initial term with optional extensions, requiring manufacturers to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencara, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Evaluation heavily weights price competitiveness at 75 percent, with smaller weightings for fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability insurance of $5 million per occurrence and network security and privacy liability of $2 million, and must demonstrate pricing flexibility through flat-price, net-price, or WAC-minus formats. The contract covers both Minnesota and Oregon participating facilities.